[go: up one dir, main page]

NL301031I2 - Plerixafor, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of metaalcomplex daarvan - Google Patents

Plerixafor, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of metaalcomplex daarvan Download PDF

Info

Publication number
NL301031I2
NL301031I2 NL301031C NL301031C NL301031I2 NL 301031 I2 NL301031 I2 NL 301031I2 NL 301031 C NL301031 C NL 301031C NL 301031 C NL301031 C NL 301031C NL 301031 I2 NL301031 I2 NL 301031I2
Authority
NL
Netherlands
Prior art keywords
sub
atoms
nitrogen
formula
fused
Prior art date
Application number
NL301031C
Other languages
English (en)
Other versions
NL301031I1 (nl
Original Assignee
Genzyme Europe B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26976666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL301031(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Europe B V filed Critical Genzyme Europe B V
Publication of NL301031I1 publication Critical patent/NL301031I1/nl
Publication of NL301031I2 publication Critical patent/NL301031I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NL301031C 2001-07-31 2020-01-22 Plerixafor, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of metaalcomplex daarvan NL301031I2 (nl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30919601P 2001-07-31 2001-07-31
US38215502P 2002-05-20 2002-05-20
PCT/US2002/024212 WO2003011277A2 (en) 2001-07-31 2002-07-30 Methods to mobilize progenitor/stem cells
EP02750370A EP1411918B1 (en) 2001-07-31 2002-07-30 Methods to mobilize progenitor/stem cells

Publications (2)

Publication Number Publication Date
NL301031I1 NL301031I1 (nl) 2020-02-05
NL301031I2 true NL301031I2 (nl) 2020-07-20

Family

ID=26976666

Family Applications (2)

Application Number Title Priority Date Filing Date
NL300537C NL300537I2 (nl) 2001-07-31 2012-06-28
NL301031C NL301031I2 (nl) 2001-07-31 2020-01-22 Plerixafor, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of metaalcomplex daarvan

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NL300537C NL300537I2 (nl) 2001-07-31 2012-06-28

Country Status (28)

Country Link
US (9) US6987102B2 (nl)
EP (3) EP2371361B1 (nl)
JP (2) JP5137288B2 (nl)
KR (2) KR100996378B1 (nl)
CN (2) CN102302493B (nl)
AT (1) ATE538785T1 (nl)
AU (1) AU2002318927B2 (nl)
BE (1) BE2019C544I2 (nl)
BR (1) BRPI0211570B8 (nl)
CA (1) CA2455559C (nl)
CY (4) CY1112633T1 (nl)
DK (2) DK2371361T3 (nl)
ES (2) ES2742730T3 (nl)
FR (2) FR12C0042I1 (nl)
HU (1) HUP0402360A2 (nl)
IL (2) IL159312A0 (nl)
LT (2) LT2371361T (nl)
LU (2) LU92033I2 (nl)
MX (1) MXPA04000982A (nl)
NL (2) NL300537I2 (nl)
NO (4) NO336989B1 (nl)
NZ (1) NZ530169A (nl)
PL (1) PL364673A1 (nl)
PT (2) PT2371361T (nl)
RU (1) RU2309741C2 (nl)
SI (2) SI2371361T1 (nl)
WO (1) WO2003011277A2 (nl)
ZA (1) ZA200400658B (nl)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04000982A (es) 2001-07-31 2004-04-20 Anormed Inc Metodos para movilizar celulas progenitoras/madre.
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
US20030220341A1 (en) 2001-12-21 2003-11-27 Gary Bridger Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US7354932B2 (en) 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
AU2004257966B2 (en) * 2003-06-27 2008-10-02 Asahi Kasei Kabushiki Kaisha Cell diffrentiation inhibitor, cell culture method using the same, liquid culture medium and cultured cell line
WO2005002522A2 (en) * 2003-06-30 2005-01-13 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Compositions and methods for treating tissue ischemia
US7417026B2 (en) 2003-08-13 2008-08-26 Children's Hospital Medical Center Mobilization of hematopoietic cells
EP1656451A2 (en) 2003-08-13 2006-05-17 Children's Hospital Medical Center Chimeric peptides for the regulation of gtpases
IL158868A0 (en) * 2003-11-13 2004-05-12 Yeda Res & Dev Methods of generating and using stem cells enriched with immature primitive progenitor
WO2005103721A1 (en) * 2004-04-20 2005-11-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 4 (cxcr4)
EP1796716A4 (en) * 2004-08-13 2010-09-08 Anormed Inc COMBINATIONS OF CHEMOKINES FOR MOBILIZING PROGENITOR / STEM CELLS
US8182806B2 (en) * 2004-09-07 2012-05-22 Johnson Lanny L Synovial villi for use with tissue engineering
US7785582B2 (en) * 2004-09-07 2010-08-31 Johnson Lanny L Use of synovium and omentum for tissue engineering
JP2008519052A (ja) * 2004-11-05 2008-06-05 ザ ジェネラル ホスピタル コーポレイション 薬剤によるヒト遊走性細胞の合目的的挙動
ES2421447T3 (es) 2005-06-13 2013-09-02 Cleveland Biolabs Inc Métodos para proteger frente a apoptosis usando lipopéptidos
EP1951046B1 (en) * 2005-08-19 2012-07-18 Genzyme Corporation Methods to enhance chemotherapy
EP2267030A1 (en) * 2005-08-25 2010-12-29 Repair Technologies, Inc. Devices, compositions and methods for the protection and repair of cells and tissues
US7927630B2 (en) * 2005-09-12 2011-04-19 Johnson Lanny L Use of autologous sediment from fluid aspirates as vehicles for drug delivery
US8518349B2 (en) 2005-09-12 2013-08-27 Lanny Johnson Use of autologous sediment from fluid aspirates as vehicles for drug delivery
US20070116680A1 (en) * 2005-11-18 2007-05-24 Rensselaer Polytechnic Institute Stem cells within gel microenvironments
CN101389329A (zh) * 2006-02-24 2009-03-18 健赞股份有限公司 增加血流和/或促进组织再生的方法
WO2007108689A2 (en) * 2006-03-21 2007-09-27 Stichting Skeletal Tissue Engineering Method for induction of differentiation of stem and progenitor cells
AR062271A1 (es) * 2006-08-07 2008-10-29 Genzyme Corp Uso de una cantidad efectiva de al menos un inhibidor de cxcr4, al menos un agonista de cxcr2 y g-csf para movilizar las celulas progenitoras y/o celulas madre
US7883698B2 (en) * 2007-01-17 2011-02-08 Maria Michejda Isolation and preservation of fetal hematopoietic and mesencymal system cells from non-controversial materials and/or tissues resulting from miscarriages and methods of therapeutic use
WO2010025416A1 (en) * 2008-08-29 2010-03-04 Genzyme Corporation Cxcr4 antagonists for kidney injury
US20130039882A1 (en) * 2009-10-28 2013-02-14 Henry Ford Health System Method to mitigate injury from radiation exposure
CN101716167B (zh) * 2009-12-08 2011-12-28 中国人民解放军军事医学科学院野战输血研究所 一类饱和胺类化合物在制备外周血造血干细胞动员药物中的应用
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
KR20140045411A (ko) 2011-05-16 2014-04-16 젠자임 코포레이션 Ｃｘｃｒ４ 길항제의 용도
EP2968563A4 (en) * 2013-03-15 2016-11-30 Leonard B Miller COMBINED TREATMENT TO IMPROVE MOU TISSUE HEALING, HEALING ADIPOSE TISSUE GRAFT, ENDOCHREST BONE SEWAGE AND OSTEOINTEGRATION
US9988973B2 (en) 2015-01-06 2018-06-05 Hamilton Sundstrand Corporation Water injector for aviation cooling system
HK1259026A1 (zh) 2015-09-18 2019-11-22 综合医院公司以麻省总医院名义经营 用於治疗癌症的抗趋除剂的局部递送
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
CA3008272A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
EP3389720A1 (en) 2015-12-18 2018-10-24 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
EP3393468B1 (en) 2015-12-22 2022-09-14 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
US11433048B2 (en) * 2016-06-16 2022-09-06 Centre National De La Recherche Scientifique CXCR4 receptor-binding compounds useful for increasing interferon level
CA3027500A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
CN109640988A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
CN116554168B (zh) 2016-06-21 2025-09-23 X4制药有限公司 Cxcr4抑制剂及其用途
US11364264B2 (en) 2016-09-09 2022-06-21 The General Hospital Corporation Ex vivo antigen-presenting cells or activated CD-positive T cells for treatment of cancer
WO2018049124A1 (en) 2016-09-09 2018-03-15 The General Hospital Corporation Hsp fusion protein with anti-chemorepellant agent for treatment of infectious disease
EP3509609A4 (en) 2016-09-09 2021-01-20 The General Hospital Corporation HYBRID HSP PROTEIN WITH ANTI-CHEMIO-REPELLENT AGENT FOR CANCER TREATMENT
WO2018106738A1 (en) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Brush-arm star polymers, conjugates and particles, and uses thereof
US10058573B1 (en) 2017-12-06 2018-08-28 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem cells
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
EP3720494A2 (en) * 2017-12-06 2020-10-14 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US10709763B2 (en) * 2017-12-19 2020-07-14 Gpcr Therapeutics, Inc. GPCR heteromer inhibitors and uses thereof
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
US12059437B2 (en) 2019-10-08 2024-08-13 The Regents Of The University Of California Methods and compositions for hematopoietic stem cell mobilization
WO2021183650A1 (en) 2020-03-10 2021-09-16 X4 Pharmaceuticals, Inc. Methods for treating neutropenia
US20230193212A1 (en) 2020-05-06 2023-06-22 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
CN118660955A (zh) 2021-10-01 2024-09-17 詹森药业有限公司 增加祖细胞生产的方法
WO2025224720A1 (en) 2024-04-24 2025-10-30 Biolinerx Ltd. Methods of selecting treatment regimen against solid tumors
CN118987175A (zh) * 2024-08-13 2024-11-22 广东壹加再生医学研究院有限公司 普乐沙褔联合粒细胞集落刺激因子在制备治疗脑梗死的药物中的应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US562476A (en) * 1896-06-23 Combined fence-wire reel and straightener
US4111199A (en) * 1977-03-31 1978-09-05 Isaac Djerassi Method of collecting transfusable granulocytes by gravity leukopheresis
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4994560A (en) 1987-06-24 1991-02-19 The Dow Chemical Company Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
DE3728525A1 (de) 1987-08-24 1989-03-16 Schering Ag Mehrkernige substituierte komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
FR2644453A1 (fr) 1989-03-20 1990-09-21 Centre Nat Rech Scient Procede de preparation de tetramines cycliques monofonctionnalisees
ES2116291T3 (es) 1989-10-23 1998-07-16 Nycomed Salutar Inc Agentes quelantes de metales en sitios multiples.
US6001826A (en) 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
FR2672051B1 (fr) 1991-01-24 1993-05-21 Guerbet Sa Nouveaux ligands macrocycliques azotes, procede de preparation, complexes polymetalliques, composition de diagnostic et therapeutique.
GB9105489D0 (en) 1991-03-15 1991-05-01 Johnson Matthey Plc Improvements in chemical compounds
GB9126677D0 (en) * 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
DE69309487T2 (de) 1992-11-13 1997-10-23 Univ Washington Peripheralisierung hämatopoietischer stammzellen
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
JPH08127539A (ja) * 1994-10-31 1996-05-21 Ajinomoto Co Inc ヒトｉｌ−１１を含有する末梢血幹細胞増加剤
GB9502022D0 (en) * 1995-02-02 1995-03-22 Abuljadayel Ilham M S A method for preparing lymphohaematopoietic progenitor cells
US5612478A (en) 1995-03-30 1997-03-18 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
US5606053A (en) 1995-05-02 1997-02-25 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
JPH0952824A (ja) * 1995-06-05 1997-02-25 Nippon Kayaku Co Ltd 末梢血液中の造血幹細胞数を増加するための薬剤
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
GB9511357D0 (en) 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US5811544A (en) * 1995-08-28 1998-09-22 Johnson Matthey Plc Process for preparing 1,4,8,11-tetraazacyclotetradecane
CA2305787A1 (en) 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
CA2731416A1 (en) * 1998-03-30 1999-10-07 Northwest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis
AU4696899A (en) * 1998-06-19 2000-01-05 General Hospital Corporation, The Modulating platelet function
CA2244554A1 (en) * 1998-07-30 2000-01-30 Vasogen Inc. Inhibition of graft versus host disease
JP2003523166A (ja) * 1998-09-29 2003-08-05 ガミダ セル リミテッド 幹細胞および前駆細胞の増殖と分化を制御する方法
US6498155B1 (en) * 1998-11-17 2002-12-24 Smithkline Beecham Corporation Methods of treating thrombocytopenia
EP1016413A1 (en) * 1998-12-30 2000-07-05 Applied Research Systems ARS Holding N.V. Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells
US6365583B1 (en) * 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
MXPA01009674A (es) 1999-03-24 2003-07-21 Anormed Inc Compuestos heterociclicos que se unen a receptores de quimiocina.
EP1189609A4 (en) * 1999-05-03 2002-10-30 Smithkline Beecham Corp CXCR-4 RECEPTOR ANTAGONISTS AND THROMBOPOIETIN MIMETIKA
AU2334301A (en) * 1999-12-17 2001-06-25 Anormed Inc. Chemokine receptor binding heterocyclic compounds
AU2001258110B2 (en) 2000-05-09 2006-10-19 British Canadian Biosciences Corp. Cxcr4 antagonist treatment of hematopoietic cells
US20040131585A1 (en) * 2000-06-05 2004-07-08 Silviu Itescu Identification and use og human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
ATE335733T1 (de) 2000-09-15 2006-09-15 Anormed Inc Chemokin rezeptor bindenden heterozyklischen verbindungen
KR20030029997A (ko) 2000-09-15 2003-04-16 아노르메드 인코포레이티드 케모킨 수용체 결합 헤테로사이클릭 화합물
HK1052011A1 (zh) 2000-09-15 2003-08-29 Anormed Inc. 趋化因子受体结合杂环化合物
JP5335171B2 (ja) 2000-09-29 2013-11-06 アノーメッド インコーポレイティド Ｎ−１保護したｎ環窒素含有環式ポリアミンの調製のためのプロセスおよびその生成物
ATE354344T1 (de) 2001-01-23 2007-03-15 P & G Clairol Inc Primäre zwischenprodukte für die oxidative haarfärbung
MXPA04000982A (es) 2001-07-31 2004-04-20 Anormed Inc Metodos para movilizar celulas progenitoras/madre.
US7169750B2 (en) 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
US20030220341A1 (en) 2001-12-21 2003-11-27 Gary Bridger Chemokine receptor binding heterocyclic compounds with enhanced efficacy
DE102014206089B4 (de) 2014-03-31 2018-01-18 BSH Hausgeräte GmbH Haushaltskältegerät mit einer Spendereinheit mit zwei Verschlusselementen an einem Ausführkanal

Also Published As

Publication number Publication date
LU92033I9 (nl) 2019-01-03
RU2309741C2 (ru) 2007-11-10
EP1411918B1 (en) 2011-12-28
US20170049747A1 (en) 2017-02-23
SI2371361T1 (sl) 2019-10-30
DK2371361T3 (da) 2019-08-19
EP1411918A2 (en) 2004-04-28
KR100996378B1 (ko) 2010-11-25
WO2003011277A2 (en) 2003-02-13
ES2742730T3 (es) 2020-02-17
KR20040020075A (ko) 2004-03-06
BRPI0211570B1 (pt) 2020-01-28
US20190216773A1 (en) 2019-07-18
NO20040407L (no) 2004-03-19
NO336989B1 (no) 2015-12-14
LUC00139I1 (nl) 2019-11-27
HK1063005A1 (en) 2004-12-10
NL300537I2 (nl) 2017-02-02
LT2371361T (lt) 2019-09-10
LU92033I2 (fr) 2012-08-27
FR19C1058I2 (fr) 2020-10-23
LTC2371361I2 (lt) 2021-09-27
CY2019038I1 (el) 2020-05-29
US7935692B2 (en) 2011-05-03
BE2019C544I2 (nl) 2021-07-19
EP3632425A1 (en) 2020-04-08
FR19C1058I1 (nl) 2019-11-22
JP2004538303A (ja) 2004-12-24
CN102302493A (zh) 2012-01-04
US20060223180A1 (en) 2006-10-05
LUC00139I2 (nl) 2021-02-10
PT2371361T (pt) 2019-09-10
CY1112633T1 (el) 2015-08-05
HUP0402360A2 (hu) 2005-02-28
CN1561208A (zh) 2005-01-05
MXPA04000982A (es) 2004-04-20
SI1411918T1 (sl) 2012-04-30
US6987102B2 (en) 2006-01-17
US20130273009A1 (en) 2013-10-17
EP2371361A1 (en) 2011-10-05
JP2008195730A (ja) 2008-08-28
RU2004105961A (ru) 2005-03-20
CY1122199T1 (el) 2020-05-29
IL159312A (en) 2015-05-31
ES2380009T3 (es) 2012-05-07
AU2002318927B2 (en) 2007-01-04
PL364673A1 (en) 2004-12-13
US20030130250A1 (en) 2003-07-10
NO2016011I1 (no) 2016-06-10
CY2012017I2 (el) 2015-08-05
US20110129448A1 (en) 2011-06-02
NL301031I1 (nl) 2020-02-05
CN102302493B (zh) 2015-08-12
BRPI0211570B8 (pt) 2021-05-25
FR12C0042I1 (fr) 2012-08-10
DK1411918T3 (da) 2012-04-23
CA2455559A1 (en) 2003-02-13
US20150246019A1 (en) 2015-09-03
EP1411918A4 (en) 2007-11-14
NO344632B1 (no) 2020-02-17
CA2455559C (en) 2012-01-10
CY2012017I1 (el) 2015-08-05
CN1561208B (zh) 2010-11-10
ZA200400658B (en) 2005-07-27
US20060193826A1 (en) 2006-08-31
BR0211570A (pt) 2004-07-13
PT1411918E (pt) 2012-03-06
NO2020003I1 (no) 2020-03-05
JP5137288B2 (ja) 2013-02-06
KR20090130152A (ko) 2009-12-17
WO2003011277A3 (en) 2003-05-22
US20080063624A1 (en) 2008-03-13
LTPA2019018I1 (lt) 2019-12-10
NO20150674A1 (no) 2015-05-27
CY2019038I2 (el) 2020-05-29
IL159312A0 (en) 2004-06-01
EP2371361B1 (en) 2019-08-07
ATE538785T1 (de) 2012-01-15
US7897590B2 (en) 2011-03-01
NZ530169A (en) 2007-04-27

Similar Documents

Publication Publication Date Title
NL301031I2 (nl) Plerixafor, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of metaalcomplex daarvan
AP1497A (en) Methods and compositions to enhance white blood cell count.
HUP0004259A2 (hu) VLA-4 által mediált leukocita adhéziót gátló szubsztituált fenilalanin-származékok, ezeket tartalmazó gyógyászati készítmények
HUP0004529A2 (hu) VLA-4 által mediált leukocita adhéziót gátló szulfonilezett dipeptid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint alkalmazásuk
EP2308877A4 (en) Imidazopyridine-2-ON DERIVATIVE
MXPA05003193A (es) Compuesto de adenina novedoso y uso del mismo.
GB0001930D0 (en) Organic compounds
KR880005093A (ko) 5-알킬벤즈이미다졸, 그의 제조방법 및 이들을 함유하는 약제학적 조성물
TW200633979A (en) Method
KR920012082A (ko) Ace 억제제로서 유용한 신규 아미노 및 니트로 함유 삼환식 화합물
PT1210320E (pt) Aminobenzofenonas como inibidores de il-1beta e tnf-alfa
EA200501148A1 (ru) Пиридилоксиметильные и бензизоксазольные азабициклические производные
MA27576A1 (fr) Nouveaux derives d'azepines tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO1999023092A3 (en) 3-aminoalkylamino-2h-1,4-benzoxa(thia-)zines and pharmaceutical compositions containing them
AR026222A1 (es) Compuestos derivados de acido antranilico
WO2007106063A3 (en) Methods for increasing blood flow and/or promoting tissue regeneration
EA200000527A2 (ru) Новые бициклические амино-пиразиноновые соединения, способ их получения и фармацевтические композиции, содержащие их
EA200200379A2 (ru) Новые соединения пиримидин-4-она, способ их получения и содержащие их фармацевтические композиции
EA200001157A2 (ru) Новые замещенные производные (дигидро)бензоксазина и (дигидро)бензотиазина, способ их получения и содержащие их фармацевтические композиции